

Loss-of-Function Mutations in *APOC3* and Risk of

New England Journal of Medicine

371, 32-41

DOI: [10.1056/nejmoa1308027](https://doi.org/10.1056/nejmoa1308027)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Genetics of coronary artery disease – A clinician's perspective. Indian Heart Journal, 2014, 66, 663-671.	0.5	12
3	APOC3 mutations lower CVD risk. Nature Reviews Cardiology, 2014, 11, 496-496.	13.7	6
4	Resurgence of targets and compounds to treat dyslipidaemia. Nature Reviews Cardiology, 2014, 11, 629-631.	13.7	7
5	Targeting APOC3 in the Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2014, 371, 2200-2206.	27.0	376
6	Evolving targets for lipid-modifying therapy. EMBO Molecular Medicine, 2014, 6, 1215-1230.	6.9	11
7	Glucagon-Like Peptide-2 Regulates Release of Chylomicrons From the Intestine. Gastroenterology, 2014, 147, 1275-1284.e4.	1.3	73
8	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 64, 2525-2540.	2.8	192
9	Triglyceride and HDL. Current Opinion in Lipidology, 2014, 25, 404-405.	2.7	0
10	Inhibition of ApoCIII. Current Opinion in Lipidology, 2014, 25, 418-422.	2.7	22
11	APOC3: Triglycerides do matter. Global Cardiology Science & Practice, 2014, 2014, 38.	0.4	5
12	Dyslipidaemia in perspective. Lancet, The, 2014, 384, 566-568.	13.7	4
13	Triglycerides and cardiovascular disease. Lancet, The, 2014, 384, 626-635.	13.7	1,005
14	HDL and cognition in neurodegenerative disorders. Neurobiology of Disease, 2014, 72, 22-36.	4.4	118
15	Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in Lipid Research, 2014, 56, 47-66.	11.6	128
16	Diabetic dyslipidemia. Metabolism: Clinical and Experimental, 2014, 63, 1469-1479.	3.4	344
17	APOC3, Coronary Disease, and Complexities of Mendelian Randomization. Cell Metabolism, 2014, 20, 387-389.	16.2	34
18	Lxr-driven enterocyte lipid droplet formation delays transport of ingested lipids. Journal of Lipid Research, 2014, 55, 1944-1958.	4.2	43
19	Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. Journal of Internal Medicine, 2015, 278, 433-446.	6.0	30

#	ARTICLE	IF	CITATIONS
20	The Copenhagen City Heart Study (Åsterbrounder Ågelsen). <i>Global Cardiology Science & Practice</i> , 2015, 2015, 33.	0.4	40
21	Natural human knockouts and the era of genotype to phenotype. <i>Genome Medicine</i> , 2015, 7, 48.	8.2	25
22	Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia. <i>Clinical Lipidology</i> , 2015, 10, 191-203.	0.4	7
23	Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. <i>Lipids in Health and Disease</i> , 2015, 14, 98.	3.0	46
24	Novel therapeutics in hypertriglyceridemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 484-491.	2.7	35
25	Dysbetalipoproteinemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 292-297.	2.7	25
26	PrÃ©dire les crises bancaires: un systÃ©me d'alerte robuste. <i>Revue FranÃ§aise D'Ã©conomie</i> , 2016, Volume XXX, 189-225.	0.1	0
27	Human Adipose Cells In Vitro Are Either Refractory or Responsive to Insulin, Reflecting Host Metabolic State. <i>PLoS ONE</i> , 2015, 10, e0119291.	2.5	10
28	Chylomicronaemiaâ€™ current diagnosis and future therapies. <i>Nature Reviews Endocrinology</i> , 2015, 11, 352-362.	9.6	242
29	Triglyceride-Rich Lipoproteins and Coronary Artery Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, e3-9.	2.4	61
30	Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. <i>Cardiology and Therapy</i> , 2015, 4, 83-93.	2.6	17
31	Modulators of Hepatic Lipoprotein Metabolism Identified in a Search for Small-Molecule Inducers of Tribbles Pseudokinase 1 Expression. <i>PLoS ONE</i> , 2015, 10, e0120295.	2.5	25
32	Saroglitazar for the treatment of dyslipidemia in diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 597-606.	1.8	59
33	Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia. <i>Lipids in Health and Disease</i> , 2015, 14, 27.	3.0	22
34	Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2267-2275.	2.8	210
35	Mendel, Molecular Biology, and Apolipoprotein C-III: A Heady Combination. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 55-56.	1.3	0
36	The Remnants of Residual Riskâ€™. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2276-2278.	2.8	19
37	Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. <i>Atherosclerosis Supplements</i> , 2015, 18, 109-111.	1.2	37

#	ARTICLE	IF	CITATIONS
38	Lipoproteins and Cardiovascular Disease Risk. <i>Contemporary Endocrinology</i> , 2015, , 57-65.	0.1	0
39	Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 989-98.	2.4	54
40	Primary Prevention With Statins. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2699-2709.	2.8	60
41	The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study. <i>European Heart Journal</i> , 2015, 36, 2446-2453.	2.2	49
42	Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2218-2224.	2.4	58
43	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. <i>Clinical Therapeutics</i> , 2015, 37, 2732-2750.	2.5	7
44	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015, 9, S1-S122.e1.	1.5	430
45	Exome-wide association analysis reveals novel coding sequence variants associated with lipid traits in Chinese. <i>Nature Communications</i> , 2015, 6, 10206.	12.8	86
46	Hypertriglyceridemia in the Genomic Era: A New Paradigm. <i>Endocrine Reviews</i> , 2015, 36, 131-147.	20.1	118
47	Œ-3 carboxylic acids for hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 123-133.	1.8	8
48	Human genetics of HDL: Insight into particle metabolism and function. <i>Progress in Lipid Research</i> , 2015, 58, 14-25.	11.6	45
49	Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. <i>Human Molecular Genetics</i> , 2015, 24, 2390-2400.	2.9	47
50	Lipid Management. , 2015, , .		1
52	Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. <i>New England Journal of Medicine</i> , 2015, 373, 438-447.	27.0	445
53	Loss of function mutation in <i>ABCA1</i> and risk of Alzheimer's disease and Cerebrovascular disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1430-1438.	0.8	106
54	Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study. <i>Atherosclerosis</i> , 2015, 241, 641-648.	0.8	16
55	Reduced high density lipoprotein cholesterol in severe hypertriglyceridemic ApoCIII transgenic mice via lowered hepatic ApoAI synthesis. <i>Biochemical and Biophysical Research Communications</i> , 2015, 462, 420-425.	2.1	2
56	Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture: Figure 1. <i>Diabetes</i> , 2015, 64, 2689-2697.	0.6	17

#	ARTICLE	IF	CITATIONS
57	Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1880-1888.	2.4	60
58	Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. <i>Cardiovascular Research</i> , 2015, 107, 579-589.	3.8	50
59	Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease. <i>European Heart Journal</i> , 2015, 36, 1601-1608.	2.2	59
60	Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. <i>Drugs</i> , 2015, 75, 1201-1228.	10.9	18
61	Mechanisms of disease: paracrine effects of adipose tissue, progenitor cell function, and epigenetics of diabetic vascular disease. <i>European Heart Journal</i> , 2015, 36, 765-767.	2.2	3
62	LDL, HDL, VLDL, and CVD Prevention: Lessons from Genetics?. <i>Current Cardiology Reports</i> , 2015, 17, 610.	2.9	11
63	Novel Mutations of Low-Density Lipoprotein Receptor Gene in China Patients with Familial Hypercholesterolemia. <i>Applied Biochemistry and Biotechnology</i> , 2015, 176, 101-109.	2.9	8
64	Developing Medicines That Mimic the Natural Successes of the Human Genome. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1562-1566.	2.8	39
66	A dose-response study of consuming high-fructose corn syrupâ€™sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. <i>American Journal of Clinical Nutrition</i> , 2015, 101, 1144-1154.	4.7	214
67	Triglycerides on the rise: should we swap seats on the seesaw?. <i>European Heart Journal</i> , 2015, 36, 774-776.	2.2	71
68	New Insights into the Regulation of Chylomicron Production. <i>Annual Review of Nutrition</i> , 2015, 35, 265-294.	10.1	140
69	Apolipoprotein CIII links islet insulin resistance to Î²-cell failure in diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2611-9.	7.1	69
70	Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. <i>Methods</i> , 2015, 81, 86-92.	3.8	42
71	Textbook of Personalized Medicine. , 2015, , .		27
72	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1â€™Full Report. <i>Journal of Clinical Lipidology</i> , 2015, 9, 129-169.	1.5	632
73	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. <i>Cardiology Clinics</i> , 2015, 33, 309-323.	2.2	15
74	Mendelian Randomization: New Applications in the Coming Age of Hypothesis-Free Causality. <i>Annual Review of Genomics and Human Genetics</i> , 2015, 16, 327-350.	6.2	298
75	Next-generation gene discovery for variants of large impact on lipid traits. <i>Current Opinion in Lipidology</i> , 2015, 26, 114-119.	2.7	5

#	ARTICLE	IF	CITATIONS
76	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2015, 26, 70-71.	2.7	0
77	PCSK9 inhibition to reduce cardiovascular disease risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 126-132.	2.3	24
78	Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients. <i>Indian Heart Journal</i> , 2015, 67, 23-26.	0.5	27
79	Recent developments in genome and exome-wide analyses of plasma lipids. <i>Current Opinion in Lipidology</i> , 2015, 26, 96-102.	2.7	24
80	HDL re-examined. <i>Current Opinion in Lipidology</i> , 2015, 26, 127-132.	2.7	35
81	Apolipoprotein C-III. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 119-125.	2.3	87
82	Human Genetics of Atherothrombotic Disease and its Risk Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 741-747.	2.4	9
83	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	8.7	144
84	Analysis of Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2055-2056.	2.8	0
85	Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2053-2055.	2.8	41
86	Protective alleles and modifier variants in human health and disease. <i>Nature Reviews Genetics</i> , 2015, 16, 689-701.	16.3	105
87	Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. <i>Atherosclerosis</i> , 2015, 242, 357-366.	0.8	144
88	Moderate Exercise Increases Affinity of Large Very Low-Density Lipoproteins for Hydrolysis by Lipoprotein Lipase. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2205-2213.	3.6	25
89	HDL Cholesterol and Risk of Type 2 Diabetes: A Mendelian Randomization Study. <i>Diabetes</i> , 2015, 64, 3328-3333.	0.6	127
91	Sex-Specific Parental Effects on Offspring Lipid Levels. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	8
92	Discovery and Optimization of Imidazopyridine-Based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7173-7185.	6.4	61
93	The UK10K project identifies rare variants in health and disease. <i>Nature</i> , 2015, 526, 82-90.	27.8	1,014
94	Secondary hypertriglyceridemia in children and adolescents. <i>Journal of Clinical Lipidology</i> , 2015, 9, S29-S40.	1.5	27

#	ARTICLE	IF	CITATIONS
95	Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes. <i>Atherosclerosis</i> , 2015, 242, 334-339.	0.8	11
97	JCL roundtable: Apolipoproteins as causative elements in vascular disease. <i>Journal of Clinical Lipidology</i> , 2015, 9, 733-740.	1.5	6
98	Mendelian randomisation applied to drug development in cardiovascular disease: a review. <i>Journal of Medical Genetics</i> , 2015, 52, 71-79.	3.2	52
99	Human knockout research: new horizons and opportunities. <i>Trends in Genetics</i> , 2015, 31, 108-115.	6.7	42
100	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. <i>Nature</i> , 2015, 518, 102-106.	27.8	581
101	Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors. <i>Current Medical Research and Opinion</i> , 2015, 31, 435-438.	1.9	4
102	Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study. <i>Clinical Medicine Insights: Cardiology</i> , 2016, 10, CMC.S38123.	1.8	4
103	Complications of Diabetes Mellitus. , 2016, , 1484-1581.		13
104	The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. <i>BMB Reports</i> , 2016, 49, 139-148.	2.4	57
105	Role of Conventional Risk Factors in Genetic Susceptibility to Cardiovascular Diseases. , 2016, , 159-176.		0
106	<div>Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside</div>. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 3077-3086.	6.7	129
107	Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia. <i>Cardiology</i> , 2016, 135, 3-12.	1.4	11
108	Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2016, 12, 171.	2.3	166
109	Hypertriglyceridemia and Cardiovascular Diseases: Revisited. <i>Korean Circulation Journal</i> , 2016, 46, 135.	1.9	39
110	Zebrafish Models for Dyslipidemia and Atherosclerosis Research. <i>Frontiers in Endocrinology</i> , 2016, 7, 159.	3.5	28
111	Lipids in Coronary Heart Disease. , 2016, , 67-80.		0
112	Genetics of Dyslipidemia. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 106, 434-8.	0.8	22
113	Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say. <i>International Journal of Clinical Practice</i> , 2016, 70, 142-146.	1.7	0

#	ARTICLE	IF	CITATIONS
114	Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?. Current Cardiology Reports, 2016, 18, 67.	2.9	74
115	Genetic insights into statin-associated diabetes risk. Current Opinion in Lipidology, 2016, 27, 125-130.	2.7	7
116	A genome-wide study of lipid response to fenofibrate in Caucasians. Pharmacogenetics and Genomics, 2016, 26, 324-333.	1.5	12
117	Using human genetics to predict the effects and side-effects of drugs. Current Opinion in Lipidology, 2016, 27, 105-111.	2.7	10
118	Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism. Current Opinion in Lipidology, 2016, 27, 14-18.	2.7	10
119	Association between different risk factors and vascular accelerated ageing (EVA study): study protocol for a cross-sectional, descriptive observational study. BMJ Open, 2016, 6, e011031.	1.9	37
120	Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study. Science, 2016, 354, .	12.6	464
121	Variants inANGPTL4and the Risk of Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2303-2306.	27.0	18
122	Identification of Shared and Unique Serum Lipid Profiles in Diabetes Mellitus and Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	12
123	Genetics of Lipid and Lipoprotein Disorders and Traits. Current Genetic Medicine Reports, 2016, 4, 130-141.	1.9	61
124	Mutation detection in Chinese patients with familial hypercholesterolemia. SpringerPlus, 2016, 5, 2095.	1.2	3
125	Merging Electronic Health Record Data and Genomics for Cardiovascular Research. Circulation: Cardiovascular Genetics, 2016, 9, 193-202.	5.1	20
126	Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk. Current Cardiology Reports, 2016, 18, 65.	2.9	13
127	Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease. American Journal of Cardiology, 2016, 118, 138-145.	1.6	134
128	Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Translational Research, 2016, 173, 30-57.	5.0	75
129	Coding Variation in <i>ANGPTL4</i> , <i>LPL</i> and <i>SVEP1</i> and the Risk of Coronary Disease. New England Journal of Medicine, 2016, 374, 1134-1144.	27.0	427
130	Alcohol consumption and risk of atrial fibrillation: Observational and genetic estimates of association. European Journal of Preventive Cardiology, 2016, 23, 1514-1523.	1.8	23
131	JCL roundtable: Lessons from genetic variants altering lipoprotein metabolism. Journal of Clinical Lipidology, 2016, 10, 448-457.	1.5	1

#	ARTICLE	IF	CITATIONS
132	Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease. <i>Nature Genetics</i> , 2016, 48, 634-639.	21.4	214
133	Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 229-239.	2.2	46
134	Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	121
135	Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. <i>Gastroenterology</i> , 2016, 151, 351-363.e28.	1.3	74
136	Impaired postprandial lipemic response in chronic kidney disease. <i>Kidney International</i> , 2016, 90, 172-180.	5.2	14
137	Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 206-212.	2.2	71
138	Metabolic Characterization of a Rare Genetic Variation Within <i>APOC3</i> and Its Lipoprotein Lipase-Independent Effects. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 231-239.	5.1	28
139	Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes. <i>Journal of Lipid Research</i> , 2016, 57, 1601-1607.	4.2	20
140	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>Atherosclerosis</i> , 2016, 253, 281-344.	0.8	1,189
141	Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?. <i>Current Atherosclerosis Reports</i> , 2016, 18, 59.	4.8	60
142	Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients. <i>Postgraduate Medicine</i> , 2016, 128, 859-864.	2.0	7
144	Cholesterol efflux capacity: An introduction for clinicians. <i>American Heart Journal</i> , 2016, 180, 54-63.	2.7	50
145	Vascular proteomics in metabolic and cardiovascular diseases. <i>Journal of Internal Medicine</i> , 2016, 280, 325-338.	6.0	39
146	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. <i>European Heart Journal</i> , 2016, 37, 2999-3058.	2.2	2,393
147	ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study. <i>European Heart Journal</i> , 2016, 38, ehw426.	2.2	45
148	APOC3 induces endothelial dysfunction through TNF- α and JAM-1. <i>Lipids in Health and Disease</i> , 2016, 15, 153.	3.0	22
149	The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1442-1451.e4.	1.5	22
150	Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. <i>Prostaglandins and Other Lipid Mediators</i> , 2016, 125, 57-64.	1.9	37

#	ARTICLE	IF	CITATIONS
151	Association of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 368-374.	5.1	8
152	Treatment of Hyperlipidemia Changes With Level of Kidney Function—Rationale. <i>Advances in Chronic Kidney Disease</i> , 2016, 23, 247-254.	1.4	8
153	Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms. <i>Bioanalysis</i> , 2016, 8, 1623-1633.	1.5	17
154	Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. <i>Atherosclerosis</i> , 2016, 253, 171-177.	0.8	42
155	Targeting ApoC-III to Reduce Coronary Disease Risk. <i>Current Atherosclerosis Reports</i> , 2016, 18, 54.	4.8	31
156	Using human genetics to discover new therapeutic targets for plasma lipids. <i>Journal of Internal Medicine</i> , 2016, 280, 487-495.	6.0	5
157	An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site. <i>Scientific Reports</i> , 2016, 6, 32700.	3.3	21
158	The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism. <i>Lipids in Health and Disease</i> , 2016, 15, 184.	3.0	40
159	Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis. <i>JAMA Internal Medicine</i> , 2016, 176, 1834.	5.1	194
160	Apolipoprotein CIII is a new player in diabetes. <i>Current Opinion in Lipidology</i> , 2016, 28, 1.	2.7	22
161	Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1408-1415.	8.6	130
162	Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 11.	6.8	28
163	Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 216-228.	1.9	8
165	Apoprotein C-III: A review of its clinical implications. <i>Clinica Chimica Acta</i> , 2016, 460, 50-54.	1.1	18
166	Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1125-1134.	3.1	23
167	Where to now in cardiovascular disease prevention. <i>Atherosclerosis</i> , 2016, 251, 483-489.	0.8	2
168	High alcohol consumption causes high IgE levels but not high risk of allergic disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1404-1413.e13.	2.9	21
169	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. <i>Diabetes</i> , 2016, 65, 1767-1778.	0.6	155

#	ARTICLE	IF	CITATIONS
170	Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 2628-2640.	3.8	97
171	Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis. <i>Meta Gene</i> , 2016, 9, 104-109.	0.6	10
172	Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. <i>Journal of Clinical Lipidology</i> , 2016, 10, 635-645.e1.	1.5	35
173	The Advent of High-Throughput Sequencing Studies of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1323-1324.	5.6	1
174	Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2016, 291, 14695-14705.	3.4	11
175	Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 65-74.	2.6	11
176	Whole-exome sequencing in individuals with multiple cardiovascular risk factors and normal coronary arteries. <i>Coronary Artery Disease</i> , 2016, 27, 257-266.	0.7	13
177	Single-Particle Tracking of Human Lipoproteins. <i>Analytical Chemistry</i> , 2016, 88, 596-599.	6.5	5
178	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. <i>Nature Communications</i> , 2016, 7, 10353.	12.8	50
179	Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population. <i>Atherosclerosis</i> , 2016, 246, 63-70.	0.8	30
180	History and future of omega-3 fatty acids in cardiovascular disease. <i>Current Medical Research and Opinion</i> , 2016, 32, 301-311.	1.9	29
181	Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. <i>Circulation Research</i> , 2016, 118, 579-585.	4.5	131
182	Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. <i>Trends in Molecular Medicine</i> , 2016, 22, 328-340.	6.7	27
183	New Era of Lipid-Lowering Drugs. <i>Pharmacological Reviews</i> , 2016, 68, 458-475.	16.0	45
184	Inactivating Variants in <i>ANGPTL4</i> and Risk of Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 374, 1123-1133.	27.0	411
185	Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 905-914.	1.5	54
187	Increased Risk for Other Cancers in Addition to Breast Cancer for <i>CHEK2</i> *1100delC Heterozygotes Estimated From the Copenhagen General Population Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1208-1216.	1.6	97
188	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. <i>Journal of Lipid Research</i> , 2016, 57, 706-713.	4.2	83

#	ARTICLE	IF	CITATIONS
189	Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2016, 45, 185-204.	3.2	20
190	From Lipids to Inflammation. <i>Circulation Research</i> , 2016, 118, 732-749.	4.5	180
191	Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. <i>Atherosclerosis</i> , 2016, 247, 161-169.	0.8	34
192	From Loci to Biology. <i>Circulation Research</i> , 2016, 118, 586-606.	4.5	54
193	Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. <i>Circulation Research</i> , 2016, 118, 547-563.	4.5	701
194	New Therapeutic Approaches to the Treatment of Dyslipidemia. <i>Cell Metabolism</i> , 2016, 23, 405-412.	16.2	67
195	Experimental Biology for the Identification of Causal Pathways in Atherosclerosis. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 1-11.	2.6	5
196	Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial. <i>Journal of Clinical Lipidology</i> , 2016, 10, 181-191.e2.	1.5	20
197	Lipids, Lipoproteins, and Cardiovascular Disease: Clinical Pharmacology Now and in the Future. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 804-814.	3.6	36
198	Slippery Slope of Triglycerides. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 97-99.	2.2	4
199	Genetics of Coronary Artery Disease. <i>Circulation Research</i> , 2016, 118, 564-578.	4.5	288
200	Cardiovascular risk reduction: the future of cholesterol lowering drugs. <i>Current Opinion in Pharmacology</i> , 2016, 27, 62-69.	3.5	7
201	Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 100-108.	2.2	138
202	Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes. <i>Journal of Lipid Research</i> , 2016, 57, 894-905.	4.2	41
203	Exome Sequencing Analysis in Severe, Early-Onset Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1353-1363.	5.6	46
204	Genetics for the Identification of Lipid Targets Beyond PCSK9. <i>Canadian Journal of Cardiology</i> , 2017, 33, 334-342.	1.7	8
205	Genetic variation in WRN and ischemic stroke: General population studies and meta-analyses. <i>Experimental Gerontology</i> , 2017, 89, 69-77.	2.8	7
206	APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. <i>Journal of Biological Chemistry</i> , 2017, 292, 3692-3705.	3.4	13

#	ARTICLE	IF	CITATIONS
207	The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities. <i>Current Atherosclerosis Reports</i> , 2017, 19, 6.	4.8	38
208	Comments on the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 72-77.	0.6	5
210	Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition. <i>Journal of Lipid Research</i> , 2017, 58, 840-852.	4.2	19
211	Genetics of coronary artery disease: discovery, biology and clinical translation. <i>Nature Reviews Genetics</i> , 2017, 18, 331-344.	16.3	448
212	From the Editor: New guidelines are coming. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1-2.	1.5	3
214	Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 937.	7.4	148
215	Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of ApoC-III. <i>Journal of the American College of Cardiology</i> , 2017, 69, 789-800.	2.8	150
216	Greater remnant lipoprotein cholesterol reduction with pitavastatin compared with pravastatin in HIV-infected patients. <i>Aids</i> , 2017, 31, 965-971.	2.2	4
217	Human genes lost and their functions found. <i>Nature</i> , 2017, 544, 171-172.	27.8	2
218	Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. <i>Nature</i> , 2017, 544, 235-239.	27.8	292
219	Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. <i>European Heart Journal</i> , 2017, 38, 2478-2486.	2.2	447
220	A decade of progress on the genetic basis of coronary artery disease. Practical insights for the internist. <i>European Journal of Internal Medicine</i> , 2017, 41, 10-17.	2.2	14
221	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1206-1212.	2.4	56
222	The Role of Emerging Risk Factors in Cardiovascular Outcomes. <i>Current Atherosclerosis Reports</i> , 2017, 19, 28.	4.8	43
223	Body Mass Index and Risk of Alzheimer's Disease: A Mendelian Randomization Study of 399,536 Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2310-2320.	3.6	54
224	Human genetic insights into lipoproteins and risk of cardiometabolic disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 113-119.	2.7	12
225	Clarifying complex inheritance. <i>Current Opinion in Lipidology</i> , 2017, 28, 308-312.	2.7	7
226	Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk. <i>American Journal of Epidemiology</i> , 2017, 186, 736-744.	3.4	28

#	ARTICLE	IF	CITATIONS
227	Investigated treatments for lipoprotein lipase deficiency and related metabolic disorders. Expert Opinion on Orphan Drugs, 2017, 5, 411-420.	0.8	1
228	The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atherosclerosis Supplements, 2017, 30, 19-27.	1.2	32
229	A New Start for Triglycerides and Remnant Cholesterol—Nonfasting. Clinical Chemistry, 2017, 63, 1418-1419.	3.2	4
230	The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy. American Journal of Cardiovascular Drugs, 2017, 17, 409-420.	2.2	11
231	Genetics of Triglycerides and the Risk of Atherosclerosis. Current Atherosclerosis Reports, 2017, 19, 31.	4.8	89
232	Apolipoprotein C-III. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1013-1014.	2.4	7
233	Genetics and Valve Calcification —. Journal of the American College of Cardiology, 2017, 69, 2949-2951.	2.8	1
234	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 2054-2063.	2.8	348
235	Effects of Torcetrapib and Statin Treatment on ApoC-III and Apoprotein-Defined Lipoprotein Subclasses (from the ILLUMINATE Trial). American Journal of Cardiology, 2017, 119, 1753-1756.	1.6	9
236	Association of apolipoprotein-CIII (apoC-III), endothelium-dependent vasodilation and peripheral neuropathy in a multi-ethnic population with type 2 diabetes. Metabolism: Clinical and Experimental, 2017, 72, 75-82.	3.4	9
237	Triglycerides: A reappraisal. Trends in Cardiovascular Medicine, 2017, 27, 428-432.	4.9	12
238	Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III. Journal of Lipid Research, 2017, 58, 1196-1203.	4.2	16
239	Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids. Endocrine Practice, 2017, 23, 100-112.	2.1	39
240	Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects. Journal of Clinical Lipidology, 2017, 11, 495-506.e3.	1.5	14
241	Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome. Journal of Endocrinological Investigation, 2017, 40, 539-546.	3.3	11
242	A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Advances in Therapy, 2017, 34, 300-323.	2.9	37
243	Triglyceride-lowering trials. Current Opinion in Lipidology, 2017, 28, 477-487.	2.7	12
244	Biomarkers of Cardiovascular Disorders. , 2017, , 611-672.		0

#	ARTICLE	IF	CITATIONS
245	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation. <i>Journal of Lipid Research</i> , 2017, 58, 2188-2196.	4.2	32
246	Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1361-1371.	1.5	12
247	The shape of things to come in lipid management: a feast of reason. <i>Current Opinion in Lipidology</i> , 2017, 28, 449-451.	2.7	0
248	VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells. <i>Diabetologia</i> , 2017, 60, 2262-2273.	6.3	29
249	The impact of APOA5 , APOB , APOC3 and ABCA1 gene polymorphisms on ischemic stroke: Evidence from a meta-analysis. <i>Atherosclerosis</i> , 2017, 265, 60-70.	0.8	51
250	A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. <i>Nature Medicine</i> , 2017, 23, 1086-1094.	30.7	88
251	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2
252	Personalized Management of Cardiovascular Disorders. <i>Medical Principles and Practice</i> , 2017, 26, 399-414.	2.4	18
253	Navigating the Future of Cardiovascular Drug Developmentâ€”Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 445-458.	2.6	8
254	In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1741-1747.	2.4	181
255	The Alzheimer's diseaseâ€”protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool. <i>Journal of Biological Chemistry</i> , 2017, 292, 15312-15320.	3.4	63
256	ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity. <i>Scientific Reports</i> , 2017, 7, 2312.	3.3	47
258	A Novel Role for RARÎ± Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening. <i>Scientific Reports</i> , 2017, 7, 5824.	3.3	10
259	What are the prospects of apolipoprotein profiling for cardiovascular disease?. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 805-807.	3.1	2
260	Human proteoforms as new targets for clinical mass spectrometry protein tests. <i>Expert Review of Proteomics</i> , 2017, 14, 691-699.	3.0	11
261	The balance of omega-3 polyunsaturated fatty acids for -reducing residual risks in patients with coronary artery disease. <i>Acta Cardiologica</i> , 2017, 72, 240-248.	0.9	10
262	Genome Editing. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2808-2821.	2.8	27
263	ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. <i>Current Atherosclerosis Reports</i> , 2017, 19, 62.	4.8	41

#	ARTICLE	IF	CITATIONS
264	Antisense Oligonucleotides for the Treatment of Hypertriglyceridemia and Hyperlipoproteinemia(a). <i>Current Pharmacology Reports</i> , 2017, 3, 458-468.	3.0	3
265	Mechanistic insights from combining genomics with metabolomics. <i>Current Opinion in Lipidology</i> , 2017, 28, 99-103.	2.7	4
266	Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL. <i>Journal of Lipid Research</i> , 2017, 58, 1893-1902.	4.2	39
267	Dyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype. <i>Current Cardiology Reports</i> , 2017, 19, 61.	2.9	12
268	Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. <i>Nature Genetics</i> , 2017, 49, 17-26.	21.4	452
269	Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases. <i>Drug Discovery Today</i> , 2017, 22, 352-365.	6.4	41
270	Leveraging human genetics to guide drug target discovery. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 352-359.	4.9	26
271	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. <i>Nature Reviews Endocrinology</i> , 2017, 13, 36-49.	9.6	509
272	Association of high-density lipoprotein cholesterol with non-fatal cardiac and non-cardiac events: a CANHEART substudy. <i>Open Heart</i> , 2017, 4, e000731.	2.3	3
273	37 Pathologische Laborbefunde (IV)., 2017, , .		0
274	Role of Intestinal LXRI± in Regulating Post-prandial Lipid Excursion and Diet-Induced Hypercholesterolemia and Hepatic Lipid Accumulation. <i>Frontiers in Physiology</i> , 2017, 8, 280.	2.8	13
275	Fatty Acids Consumption: The Role Metabolic Aspects Involved in Obesity and Its Associated Disorders. <i>Nutrients</i> , 2017, 9, 1158.	4.1	162
276	Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes. <i>Proteomes</i> , 2017, 5, 27.	3.5	12
277	Quinoa Seed Lowers Serum Triglycerides in Overweight and Obese Subjects: A Dose-Response Randomized Controlled Clinical Trial. <i>Current Developments in Nutrition</i> , 2017, 1, e001321.	0.3	38
278	Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	4.0	29
279	Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients. <i>PLoS ONE</i> , 2017, 12, e0169939.	2.5	9
280	Rare coding variants pinpoint genes that control human hematological traits. <i>PLoS Genetics</i> , 2017, 13, e1006925.	3.5	39
281	Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. <i>Lipids in Health and Disease</i> , 2017, 16, 149.	3.0	96

#	ARTICLE	IF	CITATIONS
283	Advances in Hypercholesterolemia. , 2017, , 663-693.		1
284	Genetic Influences on Blood Lipids and Cardiovascular Disease Risk. , 2017, , 571-593.		1
285	Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy. Journal of Thoracic Disease, 2017, 9, 2308-2310.	1.4	7
286	Lipid metabolism. Current Opinion in Lipidology, 2018, 29, 164-165.	2.7	2
287	Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease. European Heart Journal, 2018, 39, 2106-2116.	2.2	31
288	Effects of Different Weight Loss Approaches on CVD Risk. Current Atherosclerosis Reports, 2018, 20, 27.	4.8	31
289	How genome editing could be used in the treatment of cardiovascular diseases. Personalized Medicine, 2018, 15, 67-69.	1.5	7
290	Lipoprotein lipase regulates hematopoietic stem progenitor cell maintenance through DHA supply. Nature Communications, 2018, 9, 1310.	12.8	22
291	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 2018, 138, 770-781.	1.6	126
292	Insights from population-based analyses of plasma lipids across the allele frequency spectrum. Current Opinion in Genetics and Development, 2018, 50, 1-6.	3.3	9
293	Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Lipidology, 2018, 12, 801-809.	1.5	19
294	Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population. Annals of Internal Medicine, 2018, 168, 85.	3.9	60
295	Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C. European Heart Journal, 2018, 39, 620-622.	2.2	13
296	Advances in lipid-lowering therapy through gene-silencing technologies. Nature Reviews Cardiology, 2018, 15, 261-272.	13.7	101
297	<i>APOC3</i> Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 660-668.	2.4	70
298	Genetics of familial hypercholesterolemia. Current Opinion in Lipidology, 2018, 29, 80-86.	2.7	5
299	Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study. European Heart Journal, 2018, 39, 610-619.	2.2	42
300	Effects of evolving lipid-lowering drugs on carbohydrate metabolism. Diabetes Research and Clinical Practice, 2018, 137, 1-9.	2.8	2

#	ARTICLE	IF	CITATIONS
301	Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 197-205.	2.6	34
302	The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes. <i>Canadian Journal of Cardiology</i> , 2018, 34, 595-604.	1.7	56
303	Pharmacogenomics of blood lipid regulation. <i>Pharmacogenomics</i> , 2018, 19, 651-665.	1.3	3
304	Control of serum triglyceride levels by the apolipoprotein C3 gene and its relationship to cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2018, 29, 271-272.	2.7	2
305	Lipids and Lipoproteins in Risk Prediction. <i>Cardiology Clinics</i> , 2018, 36, 213-220.	2.2	7
306	ABCA1 and risk of dementia and vascular disease in the Danish population. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 41-51.	3.7	11
307	New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?. <i>Atherosclerosis</i> , 2018, 272, 27-32.	0.8	30
308	Lipoprotein Disorders. , 2018, , 27-46.		1
309	Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. <i>Current Opinion in Lipidology</i> , 2018, 29, 171-179.	2.7	75
310	High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III and Subclinical Atherosclerosis Measures: MESA (The Multi-Ethnic Study of Atherosclerosis). <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	19
311	CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 12-18.	2.4	23
312	Current drugs, targets, and drug delivery systems for the treatment of dyslipidemia. <i>Journal of Pharmaceutical Investigation</i> , 2018, 48, 233-241.	5.3	3
313	Plasma apolipoprotein E levels and risk of dementia: A Mendelian randomization study of 106,562 individuals. <i>Alzheimer's and Dementia</i> , 2018, 14, 71-80.	0.8	55
314	Nonfasting Triglycerides, Low-Density Lipoprotein Cholesterol, and Heart Failure Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 464-472.	2.4	56
315	High-Density Lipoprotein Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts. <i>Circulation</i> , 2018, 137, 1364-1373.	1.6	85
316	Genetic architecture: the shape of the genetic contribution to human traits and disease. <i>Nature Reviews Genetics</i> , 2018, 19, 110-124.	16.3	335
317	Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. <i>Journal of Clinical Lipidology</i> , 2018, 12, 173-184.	1.5	127
318	Effects of Short-Term Exercise in Overweight/Obese Adults with Insulin Resistance or Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials. <i>Journal of Diabetes & Metabolism</i> , 2018, 9, .	0.2	4

#	ARTICLE	IF	CITATIONS
319	Lipid Measurements. , 2018, , 88-97.		0
320	Alcohol Intake and Risk of Ischemic and Haemorrhagic Stroke: Results from a Mendelian Randomisation Study. Journal of Stroke, 2018, 20, 218-227.	3.2	21
321	Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease. Current Opinion in Lipidology, 2018, 29, 433-435.	2.7	0
322	Association between Genetic Variant of Apolipoprotein C3 and Incident Hypertension Stratified by Obesity and Physical Activity in Korea. Nutrients, 2018, 10, 1595.	4.1	4
323	Baseline levels of serum high sensitivity C reactive protein and lipids in predicting the residual risk of cardiovascular events in Chinese population with stable coronary artery disease: a prospective cohort study. Lipids in Health and Disease, 2018, 17, 273.	3.0	14
324	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	1.5	7
325	Is hypertriglyceridemia atherogenic?. Presse Medicale, 2018, 47, 757-763.	1.9	6
327	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	2.7	276
328	Absence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis. JCI Insight, 2018, 3, .	5.0	91
329	Genetics of Coronary Atherosclerosis. , 2018, , 33-44.		0
330	PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke. Circulation Genomic and Precision Medicine, 2018, 11, e002247.	3.6	0
331	Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study. PLoS Medicine, 2018, 15, e1002685.	8.4	119
332	RNA-targeted therapeutics for lipid disorders. Current Opinion in Lipidology, 2018, 29, 459-466.	2.7	54
333	Neither polyphenol-rich red wine nor fenofibrate affects the onset of type-1 diabetes mellitus in the BB rat. Laboratory Animal Research, 2018, 34, 126.	2.5	0
334	Beyond Statins: Who and When to Prescribe?. Current Diabetes Reports, 2018, 18, 126.	4.2	4
335	Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2018, 11, e000046.	3.6	10
336	High Triglycerides Are Associated With Increased Cardiovascular Events, Medical Costs, and Resource Use: A Real-World Administrative Claims Analysis of Statin-Treated Patients With High Residual Cardiovascular Risk. Journal of the American Heart Association, 2018, 7, e008740.	3.7	81
337	Rare genetic variation in mitochondrial pathways influences the risk for Parkinson's disease. Movement Disorders, 2018, 33, 1591-1600.	3.9	51

#	ARTICLE	IF	CITATIONS
338	Absolute 10-year risk of dementia by age, sex and <i>APOE</i> genotype: a population-based cohort study. <i>Cmaj</i> , 2018, 190, E1033-E1041.	2.0	71
339	Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice. <i>Lipids in Health and Disease</i> , 2018, 17, 220.	3.0	20
340	Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes. <i>JAMA Cardiology</i> , 2018, 3, 957.	6.1	55
341	APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia. <i>Current Medicinal Chemistry</i> , 2018, 25, 1567-1576.	2.4	34
342	Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese. <i>Scientific Reports</i> , 2018, 8, 8107.	3.3	13
343	The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. <i>Matrix Biology</i> , 2018, 71-72, 262-282.	3.6	36
344	Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. <i>Clinical Chemistry</i> , 2018, 64, 1006-1033.	3.2	189
345	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. <i>Journal of Lipid Research</i> , 2018, 59, 1266-1275.	4.2	62
346	A novel system to quantify intestinal lipid digestion and transport. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2018, 1863, 948-957.	2.4	22
347	Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 589-598.	3.1	34
348	Lipids, Apolipoproteins, and Inflammatory Biomarkers of Cardiovascular Risk: What Have We Learned?. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 244-256.	4.7	14
349	Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM ₂ model of NASH. <i>PLoS ONE</i> , 2018, 13, e0194568.	2.5	20
350	Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management. <i>Journal of the American College of Cardiology</i> , 2018, 72, 330-343.	2.8	152
351	Endocytosis of lipoproteins. <i>Atherosclerosis</i> , 2018, 275, 273-295.	0.8	65
352	Novel Therapeutic Targets for Managing Dyslipidemia. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 733-747.	8.7	31
353	Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 237-242.	3.0	6
354	Apolipoprotein CIII may mediate the impacts of angiotensin-like protein 8 on triglyceride metabolism. <i>Lipids in Health and Disease</i> , 2018, 17, 160.	3.0	9
355	Translating GWAS Findings to Novel Therapeutic Targets for Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 56.	2.4	21

#	ARTICLE	IF	CITATIONS
356	Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals. <i>BMC Medicine</i> , 2018, 16, 39.	5.5	22
357	Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?. <i>Current Cardiology Reports</i> , 2018, 20, 88.	2.9	18
358	Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk. <i>Journal of Lipid Research</i> , 2018, 59, 1987-2000.	4.2	19
359	Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine</i> , 2018, 50, 565-575.	3.8	36
360	HDL-cholesterol, genetics, and coronary artery disease: the myth of the "good cholesterol". <i>European Heart Journal</i> , 2018, 39, 2179-2182.	2.2	15
361	Pharmacological Management of Dyslipidemia in Atherosclerosis: Limitations, Challenges, and New Therapeutic Opportunities. <i>Angiology</i> , 2019, 70, 197-209.	1.8	18
362	Using Genetic Variants in the Targets of Lipid Lowering Therapies to Inform Drug Discovery and Development: Current and Future Treatment Options. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 568-581.	4.7	6
363	ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2145-2156.	2.4	20
364	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2019, 140, e673-e691.	1.6	282
365	HDL Cholesterol Level and Mortality Occurrence in the Elderly: Is the Good Cholesterol Always Good?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4114-4116.	3.6	6
366	Apolipoprotein Profiles in Very Preterm and Term-Born Preschool Children. <i>Journal of the American Heart Association</i> , 2019, 8, e011199.	3.7	6
367	N-acetyl galactosamine-conjugated antisense drug to <i>APOC3</i> mRNA, triglycerides and atherogenic lipoprotein levels. <i>European Heart Journal</i> , 2019, 40, 2785-2796.	2.2	159
368	Integrative analysis of loss-of-function variants in clinical and genomic data reveals novel genes associated with cardiovascular traits. <i>BMC Medical Genomics</i> , 2019, 12, 108.	1.5	8
369	Life is complicated: so is apoCIII. <i>Journal of Lipid Research</i> , 2019, 60, 1347-1349.	4.2	6
370	Rounding the corner on residual risk: Implications of REDUCE-IT for omega-3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular disease. <i>Clinical Cardiology</i> , 2019, 42, 829-838.	1.8	13
371	Plasma levels of apolipoprotein E, <i>APOE</i> genotype, and all-cause and cause-specific mortality in 105,949 individuals from a white general population cohort. <i>European Heart Journal</i> , 2019, 40, 2813-2824.	2.2	44
372	National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. <i>Journal of Clinical Lipidology</i> , 2019, 13, 860-872.	1.5	79
373	A new dawn for managing dyslipidemias: The era of rna-based therapies. <i>Pharmacological Research</i> , 2019, 150, 104413.	7.1	70

#	ARTICLE	IF	CITATIONS
374	Association of Elevated Triglycerides With Increased Cardiovascular Risk and Direct Costs in Statin-Treated Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1670-1680.	3.0	45
375	Association of Triglyceride-Lowering <i>LPL</i> Variants and LDL-C Lowering <i>LDLR</i> Variants With Risk of Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 364.	7.4	460
376	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	4.5	124
377	Moving Targets. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 349-359.	2.4	31
378	Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference. <i>Journal of Lipid Research</i> , 2019, 60, 805-818.	4.2	19
379	Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. <i>Current Atherosclerosis Reports</i> , 2019, 21, 27.	4.8	72
380	Targeting RNA to lower triglycerides: long strides from short molecules. <i>European Heart Journal</i> , 2019, 40, 2797-2800.	2.2	10
381	ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance. <i>Journal of Lipid Research</i> , 2019, 60, 1379-1395.	4.2	48
382	Recent advances in novel therapies for lipid disorders. <i>Human Molecular Genetics</i> , 2019, 28, R49-R54.	2.9	15
383	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM α) paradigm: conceptual framework and therapeutic potential. <i>Cardiovascular Diabetology</i> , 2019, 18, 71.	6.8	104
384	The effects of oleoylethanolamide, an endogenous PPAR α agonist, on risk factors for NAFLD: A systematic review. <i>Obesity Reviews</i> , 2019, 20, 1057-1069.	6.5	35
385	Implementation of public health genomics in Pakistan. <i>European Journal of Human Genetics</i> , 2019, 27, 1485-1492.	2.8	19
386	Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect against Obesity. <i>Cell</i> , 2019, 177, 597-607.e9.	28.9	192
387	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-38.	4.4	31
388	The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 6-16.	4.4	13
389	A Novel Biomarker Approach to Exploit HDL for Risk Assessment. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2146-2149.	2.8	1
390	Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. <i>Annals of Clinical Biochemistry</i> , 2019, 56, 338-356.	1.6	27
391	Blood-brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals. <i>European Journal of Epidemiology</i> , 2019, 34, 579-590.	5.7	27

#	ARTICLE	IF	CITATIONS
392	Triglycerides and cardiovascular risk: Apolipoprotein B holds the key. <i>Atherosclerosis</i> , 2019, 284, 221-222.	0.8	15
393	Genetics of Common, Complex Coronary Artery Disease. <i>Cell</i> , 2019, 177, 132-145.	28.9	166
394	Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics. <i>Journal of Internal Medicine</i> , 2019, 285, 562-577.	6.0	37
395	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. <i>Endocrine Reviews</i> , 2019, 40, 537-557.	20.1	262
396	Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1861-1870.	4.4	39
397	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. <i>Journal of Clinical Lipidology</i> , 2019, 13, 492-501.	1.5	3
398	Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis. <i>Diabetologia</i> , 2019, 62, 981-992.	6.3	22
399	Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization study. <i>EBioMedicine</i> , 2019, 41, 85-90.	6.1	33
400	Molecular analysis of APOB, SAR1B, ANGPTL3, and MTTP in patients with primary hypocholesterolemia in a clinical laboratory setting: Evidence supporting polygenicity in mutation-negative patients. <i>Atherosclerosis</i> , 2019, 283, 52-60.	0.8	15
401	Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 13.	4.2	32
402	Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia – spotlight on volanesorsen. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 389-394.	4.1	10
403	Completing the genetic spectrum influencing coronary artery disease: from germline to somatic variation. <i>Cardiovascular Research</i> , 2019, 115, 830-843.	3.8	14
404	Alternative Natural Management of Dyslipidemia. , 0, , .		1
405	Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e013790.	3.7	3
406	Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 1059-1079.	4.1	3
407	Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease. <i>Lipids in Health and Disease</i> , 2019, 18, 220.	3.0	21
408	Is hypertriglyceridemia atherogenic?. <i>Current Opinion in Lipidology</i> , 2019, 30, 291-299.	2.7	11
409	Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2019, 26, 109-116.	2.3	36

#	ARTICLE	IF	CITATIONS
410	Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cellular Signalling, 2019, 55, 53-64.	3.6	23
411	Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs. American Journal of Cardiovascular Drugs, 2019, 19, 113-131.	2.2	4
412	DNA Sequence Variation in <i>ACVR1C</i> Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. Diabetes, 2019, 68, 226-234.	0.6	31
413	Effects of <i>APOC3</i> Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 63-72.	2.4	61
414	Genetic control of the mouse HDL proteome defines HDL traits, function, and heterogeneity. Journal of Lipid Research, 2019, 60, 594-608.	4.2	19
415	Capitalizing on Insights from Human Genetics to Identify Novel Therapeutic Targets for Coronary Artery Disease. Annual Review of Medicine, 2019, 70, 19-32.	12.2	6
417	Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease. Clinical Cardiology, 2019, 42, 56-61.	1.8	25
418	Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology, 2019, 51, 131-141.	0.6	112
419	Complexity, cost, and content – three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing. Clinical Chemistry and Laboratory Medicine, 2020, 58, 858-863.	2.3	2
420	Targeting angiotensinogen with RNA-based therapeutics. Current Opinion in Nephrology and Hypertension, 2020, 29, 180-189.	2.0	21
421	Saturated hydrogen improves lipid metabolism disorders and dysbacteriosis induced by a high-fat diet. Experimental Biology and Medicine, 2020, 245, 512-521.	2.4	21
422	Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects. Journal of Internal Medicine, 2020, 288, 422-438.	6.0	25
423	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. European Journal of Preventive Cardiology, 2020, 27, 1091-1100.	1.8	61
424	Association of Genetically Predicted Lipid Levels With the Extent of Coronary Atherosclerosis in Icelandic Adults. JAMA Cardiology, 2020, 5, 13.	6.1	29
425	Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?. Expert Opinion on Pharmacotherapy, 2020, 21, 107-120.	1.8	10
426	Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence. Diabetes, Obesity and Metabolism, 2020, 22, 279-289.	4.4	33
427	Triglyceride metabolism and angiotensin-like proteins in lipoprotein lipase regulation. Clinica Chimica Acta, 2020, 503, 19-34.	1.1	40
428	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nature Immunology, 2020, 21, 30-41.	14.5	169

#	ARTICLE	IF	CITATIONS
429	Lipid alterations in adolescents with early-onset psychosis may be independent of antipsychotic medication. <i>Schizophrenia Research</i> , 2020, 216, 295-301.	2.0	10
430	A higher glycemic response to oral glucose is associated with higher plasma apolipoprotein C3 independently of BMI in healthy twins. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 459-466.	2.6	1
431	Clinical review on triglycerides. <i>European Heart Journal</i> , 2020, 41, 99-109c.	2.2	286
432	Dietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII. <i>Current Opinion in Lipidology</i> , 2020, 31, 20-26.	2.7	20
433	Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. <i>Atherosclerosis</i> , 2020, 311, 84-90.	0.8	9
434	HDL and Reverse Remnant-Cholesterol Transport (RRT): Relevance to Cardiovascular Disease. <i>Trends in Molecular Medicine</i> , 2020, 26, 1086-1100.	6.7	51
435	Hypertriglyceridemia—Causes, Significance, and Approaches to Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 616.	3.5	29
436	Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. <i>European Heart Journal Supplements</i> , 2020, 22, J21-J33.	0.1	7
437	Management of hypertriglyceridemia. <i>BMJ, The</i> , 2020, 371, m3109.	6.0	89
438	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020, 22, 74.	4.8	9
439	Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. <i>Current Atherosclerosis Reports</i> , 2020, 22, 72.	4.8	14
440	Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2020, 32, 209-218.	0.2	2
441	Genetic Variants Associated With Increased Plasma Levels of Triglycerides, via Effects on the Lipoprotein Lipase Pathway, Increase Risk of Acute Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1652-1660.e6.	4.4	30
442	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. <i>Molecular Metabolism</i> , 2020, 42, 101092.	6.5	197
443	Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. <i>European Heart Journal</i> , 2020, 41, 4024-4033.	2.2	44
444	Angiopietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. <i>Journal of Lipid Research</i> , 2020, 61, 1271-1286.	4.2	120
445	Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1675-1684.	1.8	17
446	VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2725-2735.	2.8	105

#	ARTICLE	IF	CITATIONS
447	APOC3 rs2070667 Associates with Serum Triglyceride Profile and Hepatic Inflammation in Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2020, 2020, 1-9.	1.9	6
448	Vaccination in Atherosclerosis. <i>Cells</i> , 2020, 9, 2560.	4.1	24
449	Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPTL3. <i>European Heart Journal</i> , 2020, 41, 3946-3948.	2.2	4
450	Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2095-2107.	2.4	19
451	N-acetylgalactosamine (GalNAc)-conjugates: Delivering oligonucleotide drugs to the liver. , 2020, , 641-667.		2
452	Genetic variants in SUSD2 are associated with the risk of ischemic heart disease. <i>Journal of Clinical Lipidology</i> , 2020, 14, 470-481.	1.5	4
453	The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. <i>Frontiers in Endocrinology</i> , 2020, 11, 474.	3.5	81
454	Prognostic utility of triglyceride-rich lipoprotein-related markers in patients with coronary artery disease. <i>Journal of Lipid Research</i> , 2020, 61, 1254-1262.	4.2	25
455	Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias. <i>Journal of the American College of Cardiology</i> , 2020, 76, 563-579.	2.8	52
456	Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models. <i>Frontiers in Endocrinology</i> , 2020, 11, 504.	3.5	26
457	ApoCIII: A multifaceted protein in cardiometabolic disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154395.	3.4	22
458	Advances in Genomics for Drug Development. <i>Genes</i> , 2020, 11, 942.	2.4	22
459	<i>APOE</i> and dementia " resequencing and genotyping in 105,597 individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 1624-1637.	0.8	36
460	Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3152-3164.	3.6	8
461	Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants. <i>Genes and Diseases</i> , 2022, 9, 370-380.	3.4	7
462	Triglicidos, colesterol HDL y dislipidemia aterogénica en la guía europea para el control de las dislipidemias 2019. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 32, 209-218.	0.8	3
463	A Meta-Analysis on the Association Between TNFSF4 Polymorphisms (rs3861950 T > C and rs1234313 A) Tj ETQq0 0 0 rgBT /Overloc	2.8	8
464	Gene-based therapy in lipid management: the winding road from promise to practice. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 483-493.	4.1	20

#	ARTICLE	IF	CITATIONS
465	Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma. PLoS Genetics, 2020, 16, e1008682.	3.5	31
466	Causes and Consequences of Hypertriglyceridemia. Frontiers in Endocrinology, 2020, 11, 252.	3.5	122
467	EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression. IScience, 2020, 23, 100973.	4.1	8
468	Higher ANGPTL3, apoC-III, and apoB48 dyslipidemia, and lower lipoprotein lipase concentrations are associated with dysfunctional visceral fat in adolescents with obesity. Clinica Chimica Acta, 2020, 508, 61-68.	1.1	15
469	Identifying functional non-coding variants in APOA5/A4/C3/A1 gene cluster associated with coronary heart disease. Journal of Molecular and Cellular Cardiology, 2020, 144, 54-62.	1.9	9
470	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Current Atherosclerosis Reports, 2020, 22, 18.	4.8	26
471	Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids in Health and Disease, 2020, 19, 116.	3.0	9
472	Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions. Current Atherosclerosis Reports, 2020, 22, 25.	4.8	38
473	Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype. Metabolomics, 2020, 16, 69.	3.0	3
474	Importance of Genetic Studies of Cardiometabolic Disease in Diverse Populations. Circulation Research, 2020, 126, 1816-1840.	4.5	19
475	Omega-3 fatty acid therapy for cardiovascular disease: justified or not?. Current Opinion in Cardiology, 2020, 35, 417-422.	1.8	3
476	Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Expert Review of Cardiovascular Therapy, 2020, 18, 355-361.	1.5	25
477	Role of Rare and Low-Frequency Variants in Gene-Alcohol Interactions on Plasma Lipid Levels. Circulation Genomic and Precision Medicine, 2020, 13, e002772.	3.6	11
478	Fibrate pharmacogenomics: expanding past the genome. Pharmacogenomics, 2020, 21, 293-306.	1.3	7
479	Platform to study intracellular polystyrene nanoplastic pollution and clinical outcomes. Stem Cells, 2020, 38, 1321-1325.	3.2	23
480	Low cholesterol syndrome and drug development. Current Opinion in Cardiology, 2020, 35, 423-427.	1.8	1
481	Translating genomic insights into cardiovascular medicine: Opportunities and challenges of CRISPR-Cas9. Trends in Cardiovascular Medicine, 2021, 31, 341-348.	4.9	5
482	Emerging Targets for Cardiovascular Disease Prevention in Diabetes. Trends in Molecular Medicine, 2020, 26, 744-757.	6.7	15

#	ARTICLE	IF	CITATIONS
483	Lipid nanoparticle technology for therapeutic gene regulation in the liver. <i>Advanced Drug Delivery Reviews</i> , 2020, 159, 344-363.	13.7	187
484	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. <i>Heart</i> , 2020, 106, 738-745.	2.9	28
485	Human apolipoprotein CIII levels; evaluation of three assay methods. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 230-235.	1.2	1
486	Triglycerides and residual risk. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 95-103.	2.3	42
487	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. <i>Pharmacological Research</i> , 2020, 153, 104653.	7.1	54
488	Polycaptil Gel Retard Intake Reduces Postprandial Triglycerides, Ghrelin and Appetite in Obese Children: A Clinical Trial. <i>Nutrients</i> , 2020, 12, 214.	4.1	10
489	The exchangeable apolipoproteins in lipid metabolism and obesity. <i>Clinica Chimica Acta</i> , 2020, 503, 128-135.	1.1	71
490	The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiotensin-like protein 3 reduce cardiovascular disease?. <i>Current Opinion in Lipidology</i> , 2020, 31, 140-146.	2.7	29
491	Analytic and Translational Genetics. <i>Annual Review of Biomedical Data Science</i> , 2020, 3, 217-241.	6.5	4
492	2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 3005-3015.	2.2	33
493	Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. <i>European Heart Journal</i> , 2020, 41, 2288-2299.	2.2	70
494	Hypertriglyceridemia is associated with platelet hyperactivation in metabolic syndrome patients. <i>International Journal of Clinical Practice</i> , 2020, 74, e13508.	1.7	9
495	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 147-157.	2.4	12
496	A novel NanoBiT-based assay monitors the interaction between lipoprotein lipase and GPIHBP1 in real time. <i>Journal of Lipid Research</i> , 2020, 61, 546-559.	4.2	12
497	Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition. <i>Annual Review of Medicine</i> , 2021, 72, 447-458.	12.2	12
498	New Approaches for the Prevention and Treatment of Cardiovascular Disease: Focus on Lipoproteins and Inflammation. <i>Annual Review of Medicine</i> , 2021, 72, 431-446.	12.2	9
499	Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. <i>JAMA Cardiology</i> , 2021, 6, 258.	6.1	12
500	Polymorphisms in the CETP, APOC3 and APOE genes in men with unstable atherosclerotic plaques in the coronary arteries. <i>Meta Gene</i> , 2021, 27, 100847.	0.6	0

#	ARTICLE	IF	CITATIONS
501	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. Cardiovascular Research, 2021, 117, 1033-1045.	3.8	33
502	Lipid-Lowering Drugs. , 2021, , 1-8.		0
503	Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies. Molecular Biology Reports, 2021, 48, 875-886.	2.3	16
504	Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle. International Journal of Molecular Sciences, 2021, 22, 932.	4.1	12
505	Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants. Journal of Clinical Lipidology, 2021, 15, 142-150.e2.	1.5	5
506	Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk. Journal of Nutritional Science, 2021, 10, e75.	1.9	25
507	Obesity et dyslipidemies. , 2021, , 257-262.		0
508	The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk. Journal of Lipids, 2021, 2021, 1-5.	4.8	1
509	Biomarkers. , 2021, , 31-64.		0
510	Human pluripotent stem cells – Unique tools to decipher the effects of environmental and intracellular plastic pollution on human health. Environmental Pollution, 2021, 269, 116144.	7.5	7
511	Rare versus common diseases: a false dichotomy in precision medicine. Npj Genomic Medicine, 2021, 6, 19.	3.8	14
512	Genetic and Metabolic Determinants of Plasma Levels of ANGPTL8. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1649-1667.	3.6	15
513	Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Archives of Cardiovascular Diseases, 2021, 114, 132-139.	1.6	39
514	Common Genetic Variation in MC4R Does Not Affect Atherosclerotic Plaque Phenotypes and Cardiovascular Disease Outcomes. Journal of Clinical Medicine, 2021, 10, 932.	2.4	3
515	ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets. Current Atherosclerosis Reports, 2021, 23, 20.	4.8	36
516	Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction. Cardiovascular Drugs and Therapy, 2021, 35, 677-690.	2.6	11
517	The Difference Between High Density Lipoprotein Subfractions and Subspecies: an Evolving Model in Cardiovascular Disease and Diabetes. Current Atherosclerosis Reports, 2021, 23, 23.	4.8	21
518	Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements. Science Advances, 2021, 7, .	10.3	8

#	ARTICLE	IF	CITATIONS
519	Lipid Lowering Drugs: Present Status and Future Developments. <i>Current Atherosclerosis Reports</i> , 2021, 23, 17.	4.8	41
520	Uncovering the role of apolipoprotein C-III in insulin resistance. <i>Clínica E Investigación En Arteriosclerosis (English Edition)</i> , 2021, 33, 108-115.	0.2	0
521	Genome-Wide Identification of Rare and Common Variants Driving Triglyceride Levels in a Nevada Population. <i>Frontiers in Genetics</i> , 2021, 12, 639418.	2.3	7
522	Uncovering the role of apolipoprotein C-III in insulin resistance. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 108-115.	0.8	3
523	Bayesian network meta-regression hierarchical models using heavy-tailed multivariate random effects with covariate-dependent variances. <i>Statistics in Medicine</i> , 2021, 40, 3582-3603.	1.6	1
524	Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. <i>Atherosclerosis</i> , 2021, 325, 99-109.	0.8	83
525	Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 168, 102282.	2.2	0
526	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	11.4	109
527	Apolipoprotein C3 aggravates diabetic nephropathy in type 1 diabetes by activating the renal TLR2/NF- κ B pathway. <i>Metabolism: Clinical and Experimental</i> , 2021, 119, 154740.	3.4	18
528	The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 40.	4.8	15
529	Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. <i>Journal of Clinical Lipidology</i> , 2021, 15, 556-568.	1.5	17
530	Per-Particle Triglyceride-Rich Lipoproteins Imply Higher Myocardial Infarction Risk Than Low-Density Lipoproteins: Copenhagen General Population Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2063-2075.	2.4	21
531	GPIHBP1 and ANGPTL4 Utilize Protein Disorder to Orchestrate Order in Plasma Triglyceride Metabolism and Regulate Compartmentalization of LPL Activity. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 702508.	3.7	22
532	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. <i>European Heart Journal</i> , 2021, 42, 4324-4332.	2.2	135
533	Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands. <i>Genes</i> , 2021, 12, 1168.	2.4	12
534	Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. <i>Science</i> , 2021, 373, .	12.6	130
535	The Importance of Lipoprotein Lipase Regulation in Atherosclerosis. <i>Biomedicines</i> , 2021, 9, 782.	3.2	33
536	Working towards full eradication of lipid-driven cardiovascular risk?. <i>Netherlands Heart Journal</i> , 2022, 30, 15-24.	0.8	2

#	ARTICLE	IF	CITATIONS
537	Volanesorsen for treatment of familial chylomicronemia syndrome. Expert Review of Cardiovascular Therapy, 2021, 19, 685-693.	1.5	16
538	Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications. International Journal of Molecular Sciences, 2021, 22, 8422.	4.1	7
539	Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines, 2021, 9, 985.	3.2	13
540	Metabolic-associated fatty liver disease and lipoprotein metabolism. Molecular Metabolism, 2021, 50, 101238.	6.5	195
541	Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury. Journal of the American Society of Nephrology: JASN, 2021, 32, 3146-3160.	6.1	16
542	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	2.2	303
543	APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups. Lipids in Health and Disease, 2021, 20, 113.	3.0	12
545	Assessing the dyslipidemias: to fast or not to fast?. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 97-103.	2.3	1
546	Choosing a genome editing strategy and target site. , 2021, , 21-39.		0
547	Lipoproteins in chronic kidney disease: from bench to bedside. European Heart Journal, 2021, 42, 2170-2185.	2.2	32
548	Key differences between apoC-III regulation and expression in intestine and liver. Biochemical and Biophysical Research Communications, 2017, 491, 747-753.	2.1	10
549	Serum cholesterol as a risk factor for coronary heart disease revisited. South African Journal of Clinical Nutrition, 2015, 28, 34-37.	0.7	3
550	Triglycerides as a Shared Risk Factor between Dementia and Atherosclerotic Cardiovascular Disease: A Study of 125,727 Individuals. Clinical Chemistry, 2021, 67, 245-255.	3.2	24
551	Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study. Clinical Chemistry, 2021, 67, 276-287.	3.2	16
552	Apolipoprotein genetic variants and hereditary amyloidosis. Current Opinion in Lipidology, 2021, 32, 132-140.	2.7	2
553	Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance. Current Opinion in Lipidology, 2021, 32, 103-111.	2.7	11
558	Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. Journal of Clinical Investigation, 2019, 129, 4165-4179.	8.2	76
559	Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. Journal of Clinical Investigation, 2015, 125, 3819-3830.	8.2	72

#	ARTICLE	IF	CITATIONS
560	ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. <i>Journal of Clinical Investigation</i> , 2016, 126, 2855-2866.	8.2	186
561	Apolipoprotein CIII and Angiotensin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin. <i>Journal of the Endocrine Society</i> , 2021, 5, bvaa191.	0.2	6
562	APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population. <i>F1000Research</i> , 0, 3, 270.	1.6	2
563	APOC3 may not be a predictor of risk of ischemic vascular disease in the Chinese population. <i>F1000Research</i> , 2014, 3, 270.	1.6	3
564	Analysis of Low Frequency Protein Truncating Stop-Codon Variants and Fasting Concentration of Growth Hormone. <i>PLoS ONE</i> , 2015, 10, e0128348.	2.5	4
565	Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia. <i>Heart Research - Open Journal</i> , 2017, 4, 12-17.	0.2	1
566	Diabetes in Population Isolates: Lessons from Greenland. <i>Review of Diabetic Studies</i> , 2015, 12, 320-329.	1.3	11
567	Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. <i>Current Vascular Pharmacology</i> , 2019, 17, 498-514.	1.7	38
568	The Treatment of Disorders of Lipid Metabolism. <i>Deutsches A&#x0308;rzteblatt International</i> , 2016, 113, 261-8.	0.9	55
569	iTRAQ-based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DLéisoproterenol hydrochloride in mice. <i>International Journal of Molecular Medicine</i> , 2020, 45, 793-804.	4.0	1
570	Is it time to abandon fasting for routine lipid testing?. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 919-922.	1.3	6
571	Triglyceride and cardiovascular risk: A critical appraisal. <i>Indian Journal of Endocrinology and Metabolism</i> , 2016, 20, 418.	0.4	29
572	The Lausanne Institutional Biobank: A new resource to catalyse research in personalised medicine and pharmaceutical sciences. <i>Swiss Medical Weekly</i> , 2014, 144, w14033.	1.6	14
573	Obesity and Cardiovascular Disease: The Emerging Role of Inflammation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 768119.	2.4	24
574	Apolipoproteins in vascular biology and atherosclerotic disease. <i>Nature Reviews Cardiology</i> , 2022, 19, 168-179.	13.7	88
575	Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects. <i>Journal of Proteomics</i> , 2022, 251, 104398.	2.4	7
576	Is Apo-CIII the new cardiovascular target? An analysis of its current clinical and dietetic therapies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 295-308.	2.6	7
577	A Modern Approach to Dyslipidemia. <i>Endocrine Reviews</i> , 2022, 43, 611-653.	20.1	110

#	ARTICLE	IF	CITATIONS
578	New Therapies for Lowering Triglyceride-Rich Lipoproteins. Journal of the American College of Cardiology, 2021, 78, 1817-1830.	2.8	28
580	Personalized Management of Cardiovascular Disorders. , 2015, , 479-509.		1
581	Biomarker des Lipoproteinstoffwechsels. Cardiovascular Medicine(Switzerland), 2015, 18, 53-60.	0.0	0
582	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2016, , 331-354.		0
583	Genetics of Endocrinology. , 2016, , 49-68.		1
584	VII. Triglyceride and HDL Cholesterol as Risk Factors and the Treatment Targets for Atherosclerosis. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 725-734.	0.0	0
586	Loss-of-function of neuroplasticity-related genes confers risk for human neurodevelopmental disorders. , 2018, , .		6
587	Apolipoprotein C-III. , 2018, , 1-1.		0
589	Dyslipidemia in type 2 diabetes mellitus. Arhiv Za Farmaciju, 2019, 69, 338-348.	0.5	3
590	Apolipoprotein C-III. Springer Reference Medizin, 2019, , 191-191.	0.0	0
591	Apolipoprotein C-I. Springer Reference Medizin, 2019, , 190-190.	0.0	0
596	Colesterol-no HDL como objetivo terapéutico. Clínica E Investigación En Arteriosclerosis, 2019, 31, 28-33.	0.8	3
598	Genetically-engineered hamster models: applications and perspective in dyslipidemia and atherosclerosis-related cardiovascular disease. Medical Review, 2021, 1, 92-110.	1.2	1
599	Fine genetic mapping of the chromosome 11q23.3 region in a Han Chinese population: insights into the apolipoprotein genes underlying the blood lipid-lipoprotein variances. Journal of Genetics and Genomics, 2020, 47, 756-769.	3.9	0
600	Personalized Therapy of Cardiovascular Disorders. , 2021, , 279-316.		0
601	Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. Contemporary Cardiology, 2021, , 139-158.	0.1	2
602	High-Density Lipoproteins. Contemporary Cardiology, 2021, , 341-361.	0.1	1
603	Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL) and the larger HDL from very low-density lipoprotein (VLDL). Biological Chemistry, 2021, 402, 439-449.	2.5	6

#	ARTICLE	IF	CITATIONS
604	Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins. Vestnik Medicinskoga Instituta REAVIZ ReabilitaciÄ, VraÄl ZdorovĚ1e, 2020, , 88-104.	0.2	0
605	Genetics and regulation of HDL metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159060.	2.4	2
606	HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease â Insights from randomized clinical trials and human genetics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159063.	2.4	19
607	Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis. Handbook of Experimental Pharmacology, 2020, , 1.	1.8	1
608	The forkhead box O family in insulin action and lipid metabolism. , 2020, , 247-272.		0
609	Genetic Disorders of Lipoprotein Metabolism: Diagnosis and Management. , 2020, , 387-411.		0
610	Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects. Frontiers in Cardiovascular Medicine, 2021, 8, 760140.	2.4	14
611	A Comparative Overview of Prescription Omega-3 Fatty Acid Products. P and T, 2015, 40, 826-57.	0.9	23
612	Loss-of-function of neuroplasticity-related genes confers risk for human neurodevelopmental disorders. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 68-79.	0.7	6
614	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	2.2	78
615	Association of apolipoprotein Cs with new-onset type 2 diabetes mellitus: findings from the Chinese multi-provincial cohort study. BMJ Open, 2021, 11, e052388.	1.9	2
616	Effect of APOB polymorphism rs562338 (G/A) on serum proteome of coronary artery disease patients: a âproteogenomicâ approach. Scientific Reports, 2021, 11, 22766.	3.3	3
617	Apolipoprotein CâIII predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria. Journal of Internal Medicine, 2022, 291, 338-349.	6.0	10
618	Analysis of Rare Variants in Genes Related to Lipid Metabolism in Patients with Familial Hypercholesterolemia in Western Siberia (Russia). Journal of Personalized Medicine, 2021, 11, 1232.	2.5	6
619	Apolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis. Journal of Lipid Research, 2022, 63, 100157.	4.2	9
620	Lipid-Lowering Drugs. , 2021, , 929-936.		0
621	Impact of triglyceride levels on plaque characteristics in patients with coronary artery disease. International Journal of Cardiology, 2022, 348, 134-139.	1.7	4
622	Addressing dyslipidemic risk beyond LDL-cholesterol. Journal of Clinical Investigation, 2022, 132, .	8.2	51

#	ARTICLE	IF	CITATIONS
624	Guidelines versus trial-evidence for statin use in primary prevention: The Copenhagen General Population Study. <i>Atherosclerosis</i> , 2022, 341, 20-26.	0.8	3
625	Early Investigational and Experimental Therapeutics for the Treatment of Hypertriglyceridemia. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 42.	1.6	1
626	Rare coding variants in 35 genes associate with circulating lipid levels—A multi-ancestry analysis of 170,000 exomes. <i>American Journal of Human Genetics</i> , 2022, 109, 81-96.	6.2	24
627	C-reactive protein levels and risk of dementia—Observational and genetic studies of 1 11,242 individuals from the general population. <i>Alzheimer's and Dementia</i> , 2022, 18, 2262-2271.	0.8	27
628	Atherosclerosis: Pathogenesis and Key Cellular Processes, Current and Emerging Therapies, Key Challenges, and Future Research Directions. <i>Methods in Molecular Biology</i> , 2022, 2419, 3-19.	0.9	9
629	Genetically Engineered Hamster Models of Dyslipidemia and. <i>Methods in Molecular Biology</i> , 2022, 2419, 433-459.	0.9	1
630	Therapeutic RNA-silencing oligonucleotides in metabolic diseases. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 417-439.	46.4	24
631	Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. <i>Science Advances</i> , 2022, 8, eabm1418.	10.3	46
632	Plasma Proteome Profiling of Patients With In-stent Restenosis by Tandem Mass Tag-Based Quantitative Proteomics Approach. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 793405.	2.4	2
633	Efficacy and Safety of K-877 (Pemafibrate), a Selective PPAR α Modulator, in European Patients on Statin Therapy. <i>Diabetes Care</i> , 2022, 45, 898-908.	8.6	17
634	Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2022, 19, 577-592.	13.7	59
635	A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?. <i>BioDrugs</i> , 2022, 36, 121-135.	4.6	9
636	Effects of Anthocyanin-rich Berries on the Risk of Metabolic Syndrome: A Systematic Review and Meta-analysis. <i>Review of Diabetic Studies</i> , 2022, 18, 42-57.	1.3	6
637	Approach to patients with hypertriglyceridemia. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101659.	4.7	2
640	New therapeutic approaches for the treatment of hypertriglyceridemia. <i>Herz</i> , 2022, 47, 220-227.	1.1	3
641	RNA-based therapy in the management of lipid disorders: a review. <i>Lipids in Health and Disease</i> , 2022, 21, 41.	3.0	9
643	The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 99.	3.5	7
644	HDL, heart disease, and the lung. <i>Journal of Lipid Research</i> , 2022, 63, 100217.	4.2	1

#	ARTICLE	IF	CITATIONS
645	Sedentary Behaviour and Its Relationship with Early Vascular Ageing in the General Spanish Population: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5450.	2.6	2
646	Apolipoprotein C-III in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2022, 24, 104.	3.5	3
647	HDL and ASCVD. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1377, 109-118.	1.6	0
648	Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00500.	2.5	4
649	Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	3.5	16
650	Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	3
651	Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. <i>JCI Insight</i> , 2022, 7, .	5.0	7
652	Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?. <i>Journal of Clinical Medicine</i> , 2022, 11, 3331.	2.4	2
653	The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity. <i>Advanced Biology</i> , 2022, 6, .	2.5	13
654	Hypertriglyceridemia, a causal risk factor for atherosclerosis, and its laboratory assessment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1145-1159.	2.3	1
655	To evaluate the safety and efficacy of saroglitazar among pre-diabetes and dyslipidemia. <i>International Journal of Health Sciences</i> , 0, , 13816-13823.	0.1	0
656	Safety and efficacy of therapies for chylomicronemia. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 395-405.	3.1	15
657	Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	3.4	15
658	Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies. <i>PLoS ONE</i> , 2022, 17, e0269531.	2.5	3
659	Lipoprotein Assessment in the twenty-first Century. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 459-481.	3.2	3
660	Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. <i>Journal of Clinical Medicine</i> , 2022, 11, 3884.	2.4	22
661	Hypertriglyceridemia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022, 51, 539-555.	3.2	9
663	Triglyceride-Rich Lipoproteins, Remnants, and Atherosclerotic Cardiovascular Disease Risk. <i>Current Cardiovascular Risk Reports</i> , 0, , .	2.0	0

#	ARTICLE	IF	CITATIONS
664	New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 517-532.	4.7	23
665	Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention. <i>Current Atherosclerosis Reports</i> , 2022, 24, 767-778.	4.8	7
666	There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100371.	3.0	23
667	Arrhythmic Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction: Mechanisms, Genetics, and Future Directions. <i>CJC Open</i> , 2022, 4, 959-969.	1.5	3
668	Physical activity in leisure time and at work and risk of dementia: A prospective cohort study of 117,616 individuals. <i>Atherosclerosis</i> , 2022, 360, 53-60.	0.8	6
669	Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	78
670	Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. <i>Biomedicines</i> , 2022, 10, 1938.	3.2	48
671	Association of lipid metabolism-related gene promoter methylation with risk of coronary artery disease. <i>Molecular Biology Reports</i> , 2022, 49, 9373-9378.	2.3	2
672	Lipoprotein sialylation in atherosclerosis: Lessons from mice. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	3
673	A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy. <i>Journal of Lipid and Atherosclerosis</i> , 2022, 11, 250.	3.5	1
674	Obesity, Triglycerides, Remnant Cholesterol, and Other Causal Factors in Aortic Valve Stenosis: A Review. <i>Cardiometabolic Syndrome Journal</i> , 2022, 2, 108.	0.6	1
675	Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations. <i>JCI Insight</i> , 2022, 7, .	5.0	11
676	Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9777.	4.1	22
677	Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia. <i>Endocrinology and Metabolism</i> , 2022, 37, 575-586.	3.0	13
678	Associations between Alcohol Consumption and HDL Subspecies Defined by ApoC3, ApoE and ApoJ: the Cardiovascular Health Study. <i>Current Problems in Cardiology</i> , 2023, 48, 101395.	2.4	6
679	A single-day mouse mesenteric lymph surgery in mice: an updated approach to study dietary lipid absorption, chylomicron secretion, and lymphocyte dynamics. <i>Journal of Lipid Research</i> , 2022, 63, 100284.	4.2	0
680	Recent Apolipoprotein CIII trials. <i>Current Opinion in Lipidology</i> , 2022, 33, 309-318.	2.7	4
681	Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy. <i>Journal of Clinical Lipidology</i> , 2022, 16, 850-862.	1.5	5

#	ARTICLE	IF	CITATIONS
682	Spotlight on very-low-density lipoprotein as a driver of cardiometabolic disorders: Implications for disease progression and mechanistic insights. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	6
683	Adherence to dietary guidelines and risk of dementia: a prospective cohort study of 94 184 individuals. <i>Epidemiology and Psychiatric Sciences</i> , 2022, 31, .	3.9	0
684	Icosapent Ethyl for the Prevention of Cardiovascular Events. <i>EMJ Cardiology</i> , 0, , 56-65.	0.0	0
685	Associations of Alzheimer Diseaseâ€“Protective <i>APOE</i> Variants With Age-Related Macular Degeneration. <i>JAMA Ophthalmology</i> , 2023, 141, 13.	2.5	8
687	Whole-exome sequencing identifies novel protein-altering variants associated with serum apolipoprotein and lipid concentrations. <i>Genome Medicine</i> , 2022, 14, .	8.2	1
688	Genetic analysis of DNA methylation in dyslipidemia: a case-control study. <i>PeerJ</i> , 0, 10, e14590.	2.0	1
689	Genome Editing in Dyslipidemia and Atherosclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 139-156.	1.6	1
690	VPatho: a deep learning-based two-stage approach for accurate prediction of gain-of-function and loss-of-function variants. <i>Briefings in Bioinformatics</i> , 2023, 24, .	6.5	5
691	Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 388-398.	2.4	26
692	New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3. <i>Journal of Lipid and Atherosclerosis</i> , 2023, 12, 23.	3.5	6
693	APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism. <i>Current Atherosclerosis Reports</i> , 2023, 25, 67-76.	4.8	9
694	PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2319.	4.1	7
695	Clinical Trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies. <i>Journal of the American College of Cardiology</i> , 2023, 81, 1646-1658.	2.8	7
696	What is really new in triglyceride guidelines?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2023, 30, 73-80.	2.3	0
697	Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. <i>Journal of Clinical Medicine</i> , 2023, 12, 1382.	2.4	2
698	Apolipoprotein C3 induces inflammasome activation only in its delipidated form. <i>Nature Immunology</i> , 2023, 24, 408-411.	14.5	8
699	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. , 2023, 2, 122-164.		1
701	Apolipoprotein C3 is negatively associated with estrogen and mediates the protective effect of estrogen on hypertriglyceridemia in obese adults. <i>Lipids in Health and Disease</i> , 2023, 22, .	3.0	1

#	ARTICLE	IF	CITATIONS
702	Multiomic Analysis and CRISPR Perturbation Screens Identify Endothelial Cell Programs and Novel Therapeutic Targets for Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 0, , .	2.4	3
703	Inverse effects of APOC2 and ANGPTL4 on the conformational dynamics of lid-anchoring structures in lipoprotein lipase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	6
704	Advances and Challenges for GWAS Analysis in Cardiac Diseases: A Focus on Coronary Artery Disease (CAD). <i>Current Problems in Cardiology</i> , 2023, 48, 101821.	2.4	6
705	A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease. <i>Pharmaceutics</i> , 2023, 15, 1504.	4.5	3
706	Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment. , 2024, , 32-41.e2.		0
707	Treatment Guidelines Overview. , 2024, , 113-121.e2.		0
708	Diabetes and Dyslipidemia. <i>Contemporary Cardiology</i> , 2023, , 425-472.	0.1	3
709	Leukocyte-endothelial interaction in CKD. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	0
710	Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2023, 43, 1560-1571.	2.4	3
711	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. <i>Contemporary Diabetes</i> , 2023, , 821-878.	0.0	0
712	Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes. <i>Contemporary Diabetes</i> , 2023, , 169-194.	0.0	0
713	A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD. <i>Cells</i> , 2023, 12, 1648.	4.1	4
714	Targeting microbial biofilms using genomics-guided drug discovery. , 2023, , 315-324.		0
715	Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 1013-1020.	1.8	7
716	Evolving Therapeutic Targets. , 2024, , 268-274.e1.		0
717	Special Patient Populations. , 2024, , 287-297.e2.		0
718	Triglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important?. <i>European Heart Journal</i> , 2023, 44, 4196-4198.	2.2	5
719	Genetic Risk Factors Related to Coronary Artery Disease and Role of Transforming Growth Factor Beta 1 Polymorphisms. <i>Genes</i> , 2023, 14, 1425.	2.4	3

#	ARTICLE	IF	CITATIONS
720	Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. <i>American Journal of Cardiovascular Drugs</i> , 2023, 23, 477-495.	2.2	9
721	Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. <i>European Heart Journal</i> , 2023, 44, 4157-4173.	2.2	10
722	Fibrates, Hypertriglyceridemia, and CVD Risk: Where Do We Stand After the PROMINENT Trial for Triglyceride Lowering?. <i>Current Cardiology Reports</i> , 2023, 25, 987-992.	2.9	2
723	APOE and vascular disease: Sequencing and genotyping in general population cohorts. <i>Atherosclerosis</i> , 2023, 385, 117218.	0.8	4
724	Triglyceride-Rich Lipoproteins and Remnant Cholesterol in Cardiovascular Disease. <i>Journal of Korean Medical Science</i> , 2023, 38, .	2.5	7
725	Updates in Drug Treatment of Severe Hypertriglyceridemia. <i>Current Atherosclerosis Reports</i> , 2023, 25, 701-709.	4.8	5
726	Updates in Small Interfering RNA for the Treatment of Dyslipidemias. <i>Current Atherosclerosis Reports</i> , 2023, 25, 805-817.	4.8	2
727	Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids. <i>International Journal of Molecular Sciences</i> , 2023, 24, 14844.	4.1	0
728	Severe hypertriglyceridemia: Existing and emerging therapies. , 2023, 251, 108544.		3
729	The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2024, 31, 291-301.	1.8	1
730	Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials. <i>European Heart Journal</i> , 0, , .	2.2	0
733	Apolipoprotein C3: form begets function. <i>Journal of Lipid Research</i> , 2024, 65, 100475.	4.2	2
734	RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia. , 2023, 2, .		5
735	Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance. <i>Cardiovascular Research</i> , 2024, 119, 2843-2857.	3.8	1
736	Lipid profile and NT-proBNP changes from pre-clinical to established rheumatoid arthritis: a 12 years follow up explorative study. <i>Joint Bone Spine</i> , 2023, , 105683.	1.6	0
737	Atherosclerosis is the outcome of adaptive complexity in the Arterial Endothelial Microenvironment. , 2024, , 259-277.		0
738	Unlocking the mysteries of VLDL: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. <i>Lipids in Health and Disease</i> , 2024, 23, .	3.0	0
740	Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors. <i>Journal of Lipid and Atherosclerosis</i> , 2024, 13, 2.	3.5	0

#	ARTICLE	IF	CITATIONS
741	Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events. <i>Current Opinion in Lipidology</i> , 2024, 35, 110-116.	2.7	1
742	Understanding Hypertriglyceridemia: Integrating Genetic Insights. <i>Genes</i> , 2024, 15, 190.	2.4	0
743	Rare and common coding variants in lipid metabolism-related genes and their association with coronary artery disease. <i>BMC Cardiovascular Disorders</i> , 2024, 24, .	1.7	0
744	Drug development advances in human geneticsâ€based targets. <i>MedComm</i> , 2024, 5, .	7.2	0
745	Higher testosterone is associated with higher HDL-cholesterol and lower triglyceride concentrations in older women: an observational study. <i>Climacteric</i> , 2024, 27, 282-288.	2.4	0
746	Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention. <i>Atherosclerosis</i> , 2024, 391, 117501.	0.8	0
747	Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling. <i>Clinical Proteomics</i> , 2024, 21, .	2.1	0
748	FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet. <i>Aging</i> , 0, , .	3.1	0
749	Elevated blood remnant cholesterol and triglycerides are causally related to the risks of cardiometabolic multimorbidity. <i>Nature Communications</i> , 2024, 15, .	12.8	0